85 related articles for article (PubMed ID: 22846787)
1. A drug discovery platform: a simplified immunoassay for analyzing HIV protease activity.
Kitidee K; Nangola S; Hadpech S; Laopajon W; Kasinrerk W; Tayapiwatana C
J Virol Methods; 2012 Dec; 186(1-2):21-9. PubMed ID: 22846787
[TBL] [Abstract][Full Text] [Related]
2. Expedient screening for HIV-1 protease inhibitors using a simplified immunochromatographic assay.
Kitidee K; Khamaikawin W; Thongkum W; Tawon Y; Cressey TR; Jevprasesphant R; Kasinrerk W; Tayapiwatana C
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1021():153-158. PubMed ID: 26490422
[TBL] [Abstract][Full Text] [Related]
3. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
[TBL] [Abstract][Full Text] [Related]
4. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
5. In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.
Hoffmann D; Buchberger B; Nemetz C
J Clin Virol; 2005 Apr; 32(4):294-9. PubMed ID: 15780808
[TBL] [Abstract][Full Text] [Related]
6. Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.
Benko Z; Zhang J; Zhao RY
Curr HIV Res; 2019; 17(6):429-440. PubMed ID: 31782368
[TBL] [Abstract][Full Text] [Related]
7. Impedance method for detecting HIV-1 protease and screening for its inhibitors using ferrocene-peptide conjugate/Au nanoparticle/single-walled carbon nanotube modified electrode.
Mahmoud KA; Luong JH
Anal Chem; 2008 Sep; 80(18):7056-62. PubMed ID: 18707132
[TBL] [Abstract][Full Text] [Related]
8. Protocol for a mammalian cell-based assay for monitoring the HIV-1 protease activity.
Rajakuberan C; Hilton BJ; Wolkowicz R
Methods Mol Biol; 2012; 903():393-405. PubMed ID: 22782834
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
Bartonová V; Král V; Sieglová I; Brynda J; Fábry M; Horejsí M; Kozísek M; Sasková KG; Konvalinka J; Sedlácek J; Rezácová P
Antiviral Res; 2008 Jun; 78(3):275-7. PubMed ID: 18329737
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Kempf DJ; Isaacson JD; King MS; Brun SC; Sylte J; Richards B; Bernstein B; Rode R; Sun E
Antivir Ther; 2002 Sep; 7(3):165-74. PubMed ID: 12487383
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
13. In vitro translation to study HIV protease activity.
Matsuda Z; Iga M; Miyauchi K; Komano J; Morishita K; Okayama A; Tsubouchi H
Methods Mol Biol; 2007; 375():135-49. PubMed ID: 17634600
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.
Fuse T; Watanabe K; Kitazato K; Kobayashi N
Microbes Infect; 2006 Jun; 8(7):1783-9. PubMed ID: 16815068
[TBL] [Abstract][Full Text] [Related]
16. Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment.
Huang L; Li L; Tien C; LaBarbera DV; Chen C
Sci Rep; 2019 Jan; 9(1):301. PubMed ID: 30670786
[TBL] [Abstract][Full Text] [Related]
17. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development.
Beck ZQ; Hervio L; Dawson PE; Elder JH; Madison EL
Virology; 2000 Sep; 274(2):391-401. PubMed ID: 10964781
[TBL] [Abstract][Full Text] [Related]
18. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
20. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
